Description
Product Usage Information
Western Blotting: 1:1000
Immunoprecipitation: 1:50
Storage
Supplied in 10 mM sodium HEPES (pH 7.5), 150 mM NaCl, 100 µg/ml BSA, 50% glycerol and less than 0.02% sodium azide. Store at -20°C. Do not aliquot the antibody.
Protocol
Available protocols: Western Blotting, Immunoprecipitation
Specificity / Sensitivity
GSK-3 alpha (D80E6) Rabbit Monoclonal Antibody detects endogenous levels of total GSK-3α protein. This antibody does not cross-react with GSK-3β.
Species Reactivity: Human, Mouse, Rat, Hamster, Monkey
Source / Purification
Monoclonal antibody is produced by immunizing animals with a synthetic peptide corresponding to residues surrounding Gly90 of human GSK-3α protein.
Background
Glycogen synthase kinase-3 (GSK-3) was initially identified as an enzyme that regulates glycogen synthesis in response to insulin (1). GSK-3 is a ubiquitously expressed serine/threonine protein kinase that phosphorylates and inactivates glycogen synthase. GSK-3 is a critical downstream element of the PI3K/Akt cell survival pathway whose activity can be inhibited by Akt-mediated phosphorylation at Ser21 of GSK-3α and Ser9 of GSK-3β (2,3). GSK-3 has been implicated in the regulation of cell fate in and is a component of the Wnt signaling pathway required for and mammalian development (4). GSK-3 has been shown to regulate cyclin D1 proteolysis and subcellular localization (5). GSK-3α regulates the production of amyloid-β peptides, a major component of the plaques that accumulate with progression of Alzheimer disease. Administration of therapeutic concentrations of lithium, a GSK-3 inhibitor, attenuates amyloid-β production by specifically inhibiting the cleavage of amyloid precursor protein (APP) by γ-secretase, blocking accumulation of amyloid-β peptides in the brains of mice that overproduce APP (6).
Alternate Names
DKFZp686D0638; glycogen synthase kinase 3 alpha; Glycogen synthase kinase-3 alpha; GSK-3 alpha; GSK3A; GSK3alpha; Serine/threonine-protein kinase GSK3A
